Literature DB >> 23241735

Thrombomodulin in sepsis.

M Levi1, T Van Der Poll.   

Abstract

Thrombomodulin has a pivotal role in the protein C system that is important in the pathogenesis of sepsis. In sepsis, endothelial cell expression of thrombomodulin is strongly downregulated, causing an impaired activation of protein C that is central in the modulation of coagulation activation and inflammatory processes. In addition, thrombomodulin itself has marked immunomodulatory effects, targeting neutrophil adhesion, complement activation and cytokine generation. Several preclinical studies in experimental sepsis models have shown that administration of soluble thrombomodulin is capable of improving the derangement of coagulation, ameliorates inflammatory responses and may restore organ dysfunction. Initial clinical studies in patients with disseminated intravascular coagulation, of whom a significant proportion were patients with sepsis, demonstrate a beneficial effect of recombinant soluble thrombomodulin on restoration of coagulation and improvement of organ failure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23241735

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN: 0375-9393            Impact factor:   3.051


  19 in total

Review 1.  Impact of thrombosis on pulmonary endothelial injury and repair following sepsis.

Authors:  Colin E Evans; You-Yang Zhao
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-01-27       Impact factor: 5.464

Review 2.  The coagulopathy of acute sepsis.

Authors:  Jeff Simmons; Jean-Francois Pittet
Journal:  Curr Opin Anaesthesiol       Date:  2015-04       Impact factor: 2.706

Review 3.  Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin.

Authors:  Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2013-11-12       Impact factor: 2.490

4.  Endothelial Dysfunction is Associated With Increased Incidence, Worsened Severity, and Prolonged Duration of Acute Kidney Injury After Severe Trauma.

Authors:  Gabrielle E Hatton; Kayla D Isbell; Hanne H Henriksen; Jakob Stensballe; Martin Brummerstedt; Pär I Johansson; Lillian S Kao; Charles E Wade
Journal:  Shock       Date:  2021-03-01       Impact factor: 3.533

5.  Enhanced expression of cell-specific surface antigens on endothelial microparticles in sepsis-induced disseminated intravascular coagulation.

Authors:  Hisatake Matsumoto; Kazuma Yamakawa; Hiroshi Ogura; Taichin Koh; Naoya Matsumoto; Takeshi Shimazu
Journal:  Shock       Date:  2015-05       Impact factor: 3.454

6.  A thrombomodulin mutation that impairs active protein C generation is detrimental in severe pneumonia-derived gram-negative sepsis (melioidosis).

Authors:  Liesbeth M Kager; W Joost Wiersinga; Joris J T H Roelofs; Onno J de Boer; Hartmut Weiler; Cornelis van 't Veer; Tom van der Poll
Journal:  PLoS Negl Trop Dis       Date:  2014-04-24

7.  Diagnostic and prognostic utility of tissue factor for severe sepsis and sepsis-induced acute lung injury.

Authors:  Mingming Xue; Zhan Sun; Mian Shao; Jun Yin; Zhi Deng; Jin Zhang; Lingyu Xing; Xiaoliang Yang; Bin Chen; Zhimin Dong; Yi Han; Si Sun; Yuxin Wang; Chenling Yao; Xun Chu; Chaoyang Tong; Zhenju Song
Journal:  J Transl Med       Date:  2015-05-30       Impact factor: 5.531

8.  Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan.

Authors:  Kazuma Yamakawa; Yutaka Umemura; Mineji Hayakawa; Daisuke Kudo; Masamitsu Sanui; Hiroki Takahashi; Yoshiaki Yoshikawa; Toshimitsu Hamasaki; Satoshi Fujimi
Journal:  Crit Care       Date:  2016-07-29       Impact factor: 9.097

Review 9.  Disseminated intravascular coagulation.

Authors:  A Venugopal
Journal:  Indian J Anaesth       Date:  2014-09

10.  Pharmacological inhibitors of TRPV4 channels reduce cytokine production, restore endothelial function and increase survival in septic mice.

Authors:  Thomas Dalsgaard; Swapnil K Sonkusare; Cory Teuscher; Matthew E Poynter; Mark T Nelson
Journal:  Sci Rep       Date:  2016-09-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.